Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;9(6):1005-1013.
doi: 10.21037/jgo.2018.05.04.

The role of lineage specifiers in pancreatic ductal adenocarcinoma

Affiliations
Review

The role of lineage specifiers in pancreatic ductal adenocarcinoma

Soledad A Camolotto et al. J Gastrointest Oncol. 2018 Dec.

Abstract

Over the last decade, multiple genomics studies have led to the identification of discrete molecular subtypes of pancreatic ductal adenocarcinoma. A general theme has emerged that most pancreatic ductal adenocarcinoma (PDAC) can be grouped into two major subtypes based on cancer cell autonomous properties: classical/pancreatic progenitor and basal-like/squamous. The classical/progenitor subtype expresses higher levels of lineage specifiers that regulate endodermal differentiation than the basal-like/squamous subtype. The basal-like/squamous subtype confers a worse prognosis, raising the possibility that loss of these lineage specifiers might enhance the malignant potential of PDAC. Here, we discuss several of these differentially expressed lineage specifiers and examine the evidence that they might play a functional role in PDAC biology.

Keywords: Lineage specifier; molecular subtype; transcription factor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Simplified schematic representation of transcriptional hierarchy and regulatory interplay between pancreatic lineage specifiers (65). The strength of these regulatory interactions appears to vary by cell type.

Similar articles

Cited by

References

    1. Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends Cancer 2017;3:336-46. 10.1016/j.trecan.2017.04.005 - DOI - PubMed
    1. Chiaravalli M, Reni M, O'Reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treat Rev 2017;60:32-43. 10.1016/j.ctrv.2017.08.007 - DOI - PubMed
    1. Ramos MC, Boulaiz H, Grinan-Lison C, et al. What's new in treatment of pancreatic cancer: a patent review (2010-2017). Expert Opin Ther Pat 2017;27:1251-66. 10.1080/13543776.2017.1349106 - DOI - PubMed
    1. Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines 2017;5:E65. 10.3390/biomedicines5040065 - DOI - PMC - PubMed
    1. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015;47:1168-78. 10.1038/ng.3398 - DOI - PMC - PubMed